跳至主要内容
临床试验/NCT04285411
NCT04285411已完成不适用

Results of the SpO2 and Pulse Rate Accuracy Comparison of VitalDetect™ to Arterial Blood CO-Oximetry and Reference ECG

Vital USA, Inc.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2019年11月4日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1
主要终点
Evaluate SpO2 Accuracy Per Standards for Pulse Oximetry.

研究概览

简要总结

Clinical Investigation Plan: Vital USA SpO2 Accuracy Comparison to Arterial Blood CO-Oximetry Study ID# PR 2019-353, Version: Rev 1, Date: 15 Oct 2019 Study Dates: November 4-5, 2019

详细描述

An SpO2 accuracy comparison was conducted as part of the final validation of the VitalDetect™ pulse oximetry system. The study was conducted in accordance to Code of Federal Regulations (CFR) for Non-Significant Risk (NSR) investigational studies, following International Standards Organization (ISO) 14155:2011 as appropriate and the pulse oximetry guidelines of ISO 80601-2-61:2017 applicable sections, and Pulse Oximeters - Premarket Notifications Submissions [510(k)s] Guidance For Industry and Food and Drug Administration Staff (issued: March 4, 2013).

The purpose of this study was to validate the SpO2 accuracy of the VitalDetect™ pulse oximetry system during non-motion conditions over the range of 70-100% SaO2 as compared to arterial blood samples assessed by CO-Oximetry. It was expected that the Accuracy Root Mean Square (ARMS) performance of the oximetry system would meet the required specification of ARMS of 3.0% or less.

A secondary goal was to evaluate the pulse rate performance simultaneously collected over the SpO2 range covered. The Pulse Rate Accuracy Root Mean Square (Arms) performance of the VitalDetect™ pulse oximetry system, were expected to meet a specification of 3 bpm.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 52 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •10-15 Adults with a minimum of 3 males and a minimum of 3 females, with the balance made up of either
  • •Subject must have the ability to understand and provide written informed consent
  • •Subject is 18 to 50 years of age
  • •Subject must be willing and able to comply with study procedures and duration
  • •Subject is a non-smoker or who has not smoked within 2 days prior to the study

排除标准

  • •Subject is considered as being morbidly obese (defined as BMI >39.5).
  • •Compromised circulation, injury, or physical malformation of fingers, wrist, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)
  • •Female subjects that are actively trying to get pregnant or are pregnant (confirmed by positive urine pregnancy test unless the subject is known to be not of child-bearing potential).
  • •Smoker Subjects who have refrained will be screened for COPD levels >3% as assessed with a Radical 7 (Rainbow)
  • •Subjects with known respiratory conditions such as: (self-reported):
  • •uncontrolled / severe asthma,
  • •pneumonia / bronchitis,
  • •shortness of breath / respiratory distress,
  • •unresolved respiratory or lung surgery with continued indications of health issues,
  • •emphysema, COPD, lung disease.
  • •Subjects with known heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review)
  • •hypertension: systolic >140mmHg, Diastolic >90mmHg on 3 consecutive readings (reviewed during health screen).
  • •have had cardiovascular surgery
  • •Chest pain (angina)
  • •heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
  • •previous heart attack
  • •blocked artery
  • •unexplained shortness of breath
  • •congestive heart failure (CHF)
  • •history of stroke
  • •transient ischemic attack
  • •carotid artery disease
  • •myocardial ischemia
  • •myocardial infarction
  • •cardiomyopathy
  • •Self-reported health conditions as identified in the Health Assessment Form (self-reported)
  • •uncontrolled thyroid disease,
  • •kidney disease / chronic renal impairment,
  • •history of seizures (except childhood febrile seizures),
  • •history of unexplained syncope,
  • •recent history of frequent migraine headaches,
  • •recent symptomatic head injury (within the last 2 months)
  • •cancer / chemotherapy
  • •Subjects with known clotting disorders (self-reported)

研究组 & 干预措施

ARMS SpO2 70-100%

Experimental

Comparison to Reference CO-Oximetry

干预措施: Accuracy of the VitalDetect™ pulse oximetry system (Device)

结局指标

主要结局

Evaluate SpO2 Accuracy Per Standards for Pulse Oximetry.

时间窗: 90 Seconds

This study was a comparative, single-center, non-randomized study conducted to evaluate the SpO2 accuracy per standards and guidelines identified above for SpO2 accuracy for pulse oximetry equipment over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison. As a secondary goal, the pulse rate accuracy was compared to ECG Heart Rate realized over the range throughout the hypoxia procedure. Testing was conducted under normal office environment conditions.

次要结局

  • The Pulse Rate Accuracy Compared to ECG Heart Rate.(90 Seconds)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验